Arbios Systems Inc  

(Public, OTCMKTS:ARBI)   Watch this stock  
Find more results for PINK:ARBI
0.00000 (0.00%)
May 23 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.01
Open     -
Vol / Avg. 0.00/40.00
Mkt cap 125,000.00
P/E     -
Div/yield     -
EPS     -
Shares 50.00M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -89.23% -122.09%
Return on average equity - -236.26%
CDP Score - -


80 Commerce Dr
ALLENDALE, NJ 07401-1638
United States - Map
+1-201-9951919 (Phone)
+1-201-9950095 (Fax)

Website links


Arbios Systems, Inc. (Arbios) is a medical device and cell-therapy company focused on the development of products for the treatment of liver failure. The Company’s lead product candidates under development consist of a extracorporeal blood purification therapy called the SEPET Liver Assist Device and an extracorporeal, bioartificial liver therapy referred to as the HepatAssist Cell-Based Liver Support System that incorporate porcine pig liver cells. In October 2008, Arbios announced that it has sold all its rights and interest in its bioartificial liver system, HepatAssist, to HepaLife Technologies, Inc. On January 9, 2009, Arbios announced that it filed for protection under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.